Literature DB >> 33624744

Soluble fms-like tyrosine kinase-1 and angiotensin2 target calcitonin gene-related peptide family peptides in maternal vascular smooth muscle cells in pregnancy†.

Madhu Chauhan1, Ancizar Betancourt1, Meena Balakrishnan1, Akansha Mishra1, Karin Fox1, Michael Belfort1, Chandra Yallampalli1.   

Abstract

Calcitonin gene-related peptide (CALCB), adrenomedullin (ADM), and adrenomedullin2 (ADM2) are hypotensive peptides that belong to CALCB family of peptides. Goal of this study was to identify the effect of fms-like tyrosine kinase (sFLT-1) and angiotensin2 (Ang2) on the function of these peptides in OA smooth muscle cells (OASMC) and assess the sensitivity of OA for these peptides in preeclampsia (PE) and normotensive pregnancy.
METHODS: Peptide function was assessed by Cyclic adenosine monophosphate (cAMP) assays and wire myograph; mRNA expression by Polymerase chain reaction (PCR) and protein-protein interaction by proximity ligation assay and co-immunoprecipitation.
FINDINGS: All three peptides increased cAMP synthesis in the order of efficacy CALCB > ADM = ADM2 and vascular endothelial growth factor (VEGF) mRNA in OASMC (P < 0.05); sFLT-1 mediated decrease in cAMP synthesis (P < 0.05) is differentially rescued by all three CALCB family peptides in OASMC (P < 0.005); sFLT-1 decreased receptor activity-modifying protein (RAMP)1 and RAMP2 mRNA expression (P < 0.05); Ang2 decreased the expression of calcitonin-receptor-like receptor and RAMP1 mRNA and desensitized CALCB and ADM2 receptors in OASMC (P < 0.05); sFLT-1 increased RAMP1and Ang2 type 1 receptor (AT1R) interaction in OASMC which is inhibited in presence of all three peptides; and all three peptides relax OA in PE with enhanced ADM2 response (P < 0.05).
CONCLUSION: sFLT-1 and Ang2 impair OASMC mediated functional responses of CALCB family peptides which can be inhibited by respective peptide treatment. The sensitivity of OA for CALCB, ADM, and ADM2-mediated relaxation is retained in PE.
© The Author(s) 2021. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  angiotensin 2; cAMP; calcitonin gene-related peptides; pregnancy; sFLT-1; vascular smooth muscle cells

Mesh:

Substances:

Year:  2021        PMID: 33624744      PMCID: PMC8111240          DOI: 10.1093/biolre/ioab026

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  39 in total

Review 1.  RAMPs and CGRP receptors.

Authors:  James Barwell; Denise Wootten; John Simms; Debbie L Hay; David R Poyner
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

2.  AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration.

Authors:  S AbdAlla; H Lother; U Quitterer
Journal:  Nature       Date:  2000-09-07       Impact factor: 49.962

3.  Bradykinin increases BP in endotoxemic rat: functional and biochemical evidence of angiotensin II AT1 /bradykinin B2 receptor heterodimerization.

Authors:  Elaine Leocádia Anton; Daniel Fernandes; Jamil Assreuy; José Eduardo da Silva-Santos
Journal:  Br J Pharmacol       Date:  2019-05-13       Impact factor: 8.739

4.  Placenta growth factor and vascular endothelial growth factor a have differential, cell-type specific patterns of expression in vascular cells.

Authors:  Lingjin Xiang; Rohan Varshney; Nabil A Rashdan; Jennifer H Shaw; Pamela G Lloyd
Journal:  Microcirculation       Date:  2014-07       Impact factor: 2.628

5.  Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia.

Authors:  Anna E Stanhewicz; Sandeep Jandu; Lakshmi Santhanam; Lacy M Alexander
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

6.  Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation.

Authors:  Rohit Khurana; Lieve Moons; Shahida Shafi; Aernout Luttun; Désiré Collen; John F Martin; Peter Carmeliet; Ian C Zachary
Journal:  Circulation       Date:  2005-05-23       Impact factor: 29.690

7.  Adrenomedullin antagonist treatment during early gestation in rats causes fetoplacental growth restriction through apoptosis.

Authors:  Josthna Penchalaneni; Sunil J Wimalawansa; Chandrasekhar Yallampalli
Journal:  Biol Reprod       Date:  2004-06-30       Impact factor: 4.285

Review 8.  Calcitonin gene related family peptides: importance in normal placental and fetal development.

Authors:  Chandra Yallampalli; Madhu Chauhan; Janice Endsley; Kunju Sathishkumar
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

9.  Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling.

Authors:  Cissy Chenyi Zhou; Shakil Ahmad; Tiejuan Mi; Shahrzad Abbasi; Lingwei Xia; Mary-Clare Day; Susan M Ramin; Asif Ahmed; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

10.  A Novel α-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure.

Authors:  Aisah A Aubdool; Pratish Thakore; Fulye Argunhan; Sarah-Jane Smillie; Moritz Schnelle; Salil Srivastava; Khadija M Alawi; Elena Wilde; Jennifer Mitchell; Keith Farrell-Dillon; Daniel A Richards; Giuseppe Maltese; Richard C Siow; Manasi Nandi; James E Clark; Ajay M Shah; Anette Sams; Susan D Brain
Journal:  Circulation       Date:  2017-04-26       Impact factor: 29.690

View more
  1 in total

1.  Calcitonin Gene Related Peptide, Adrenomedullin, and Adrenomedullin 2 Function in Uterine Artery During Human Pregnancy.

Authors:  Madhu Chauhan; Ancizar Betancourt; Meena Balakrishnan; Akansha Mishra; Jimmy Espinosa; Alireza A Shamshirsaz; Karin Fox; Michael Belfort; Chandra Yallampalli
Journal:  Endocrinology       Date:  2022-01-01       Impact factor: 5.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.